Diabetic Peripheral Neuropathic Pain: key endpoint results by drug

The key endpoints of Diabetic Peripheral Neuropathic Pain trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Diabetic Peripheral Neuropathic Pain page.

Average daily pain, change

Average daily pain, change in Diabetic Peripheral Neuropathic Pain: 9 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Duloxetine-3.1-2.6 (Pregabalin)—wk 12 · n 120NCT00385671 Phase 4, secondary
Eslicarbazepine acetate-1.8-1.6−0.21200 mg QD · wk 17 · n 85NCT00980746 Phase 2, primary
Gabapentin-3.1-2.6 (Pregabalin)—wk 12 · n 120NCT00385671 Phase 4, secondary
Mirogabalin-1.8-1.5−0.230 mg/Day · wk 7 · n 90NCT01504412 Phase 2, primary
Nabiximols-1.7-1.6−0.1wk 14 · n 146NCT00710424 Phase 3, primary
Perampanel-1.9-2.5+0.68 mg · wk 12 · n 70NCT00505284 Phase 2/3, primary
Pregabalin-1.3-0.9−0.4wk 8 · n 161NCT00141219 Phase 3, secondary
Suzetrigine-2.2-2.1 (Pregabalin)—Low Dose · wk 12 · n 24NCT05660538 Phase 2, primary
Tapentadol-2.6-2.6±0wk 12 · n 60NCT01124617 Phase 2, primary

Drugs checked with no result here: 14 not reported, 2 not posted, 1 trial running.

30% pain reduction

30% pain reduction in Diabetic Peripheral Neuropathic Pain: 5 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Duloxetine56.7%51.2% (Pregabalin)—wk 12 · n 120NCT00385671 Phase 4, secondary
Gabapentin56.7%51.2% (Pregabalin)—wk 12 · n 120NCT00385671 Phase 4, secondary
Nabiximols36.2%39.9%−3.7wk 14 · n 149NCT00710424 Phase 3, primary
Pregabalin50.3%44.3%+6wk 9 · n 312NCT01332149 Phase 3, secondary
Suzetrigine70.8%44.9% (Pregabalin)—Low Dose · wk 12 · n 24NCT05660538 Phase 2, secondary

Drugs checked with no result here: 17 not reported, 3 not posted, 1 trial running.

50% pain reduction

50% pain reduction in Diabetic Peripheral Neuropathic Pain: 5 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Duloxetine41.7%37.8% (Pregabalin)—wk 12 · n 120NCT00385671 Phase 4, secondary
Gabapentin41.7%37.8% (Pregabalin)—wk 12 · n 120NCT00385671 Phase 4, secondary
Pregabalin26.1%14.3%+11.8wk 8 · n 161NCT00141219 Phase 3, secondary
Suzetrigine41.7%22.4% (Pregabalin)—Low Dose · wk 12 · n 24NCT05660538 Phase 2, secondary
Tapentadol40.4%28.9%+11.5wk 15 · n 166NCT01041859 Phase 3, secondary

Drugs checked with no result here: 17 not reported, 3 not posted, 1 trial running.

Sleep interference, change

Sleep interference, change in Diabetic Peripheral Neuropathic Pain: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Lacosamide-1.8-1.6−0.2400 mg/day · wk 16 · n 186NCT00350103 Phase 3, secondary
Perampanel-1.1-2.2+18 mg · wk 15 · n 70NCT00505284 Phase 2/3, secondary
Pregabalin-1.4-0.7−0.6600 mg/day · wk 13 · n 45NCT00553475 Phase 3, secondary
Suzetrigine-2.2-2.4 (Pregabalin)—Low Dose · wk 12 · n 24NCT05660538 Phase 2, secondary

Drugs checked with no result here: 18 not reported, 3 not posted, 1 trial running.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 26 approved or late-stage drugs with a featured trial in Diabetic Peripheral Neuropathic Pain were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.